Skip to Main Content

The U.S. Food and Drug Administration has authorized the use of a digital product that relies on artificial intelligence to treat patients with chronic insomnia, Boston-based Pear Therapeutics said Thursday.

The company’s product, called Somryst, uses a smartphone or tablet to deliver therapeutic recommendations to patients, such as when they should go to bed and rise, and how to identify and control behavioral patterns that may interfere with sleep.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!